About
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2014-06-27. The firm focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company’s offered product is portable neuromodulation stimulator (PoNS) device. PoNS is an authorized class II, non-implantable, medical device in Canada intended for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation.
Annual results
Reported figures, USD
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 6.0M | -40.0M | -666.7% | — |
| 2024 | — | -11.0M | — | -11.0M |
| 2023 | — | -8.0M | — | -10.4M |
| 2022 | — | -14.0M | — | -14.3M |
| 2021 | — | -18.0M | — | -13.4M |
SOL.X in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Solana Co are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.